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The effects of route and vehicle on blood and milk levels of
decabromodiphenyl ether (DecaBDE; CASRN 1163-19-5) were
investigated in the rat to assist in the design and conduct of a
developmental neurotoxicity study. Blood plasma and/or milk
concentrations were determined in dams, fetuses, and/or nursing pups after repeated DecaBDE administration by gavage
throughout gestation or gestation and lactation using corn oil
(CO) or soyaphospholipon/Lutrol F 127-water (SPL) as the vehicle. The impact of vehicle on plasma levels was also investigated in pups derived from naive dams after a single postnatal

dose. This study reports for the first time fetal and neonatal
plasma concentrations concurrent with those of maternal
plasma and/or milk. Higher concentrations of DecaBDE were
achieved in plasma and in milk with CO than with SPL. Furthermore, pups derived from dams treated with only SPL were lower
in body weight, compared with those from dams treated with
either CO, CO and DecaBDE, or SPL and DecaBDE. The study
further shows that exposure to DecaBDE is relatively consistent
across the dose range of 100 to 1000 mg/(kg 䡠 day) when administered in CO.

Introduction

The primary component of the commercial DecaBDE product is
the 2,2⬘,3,3⬘,4,4⬘,5,5⬘,6,6⬘-decabromodiphenyl ether congener
(BDE-209). In 2000, the U.S. National Research Council issued a
chronic oral reference dose1 for DecaBDE of 4 mg/(kg 䡠 day) (National
Research Council, 2000). This value was derived from DecaBDE’s
extensive toxicology database, which includes evaluations on subchronic and chronic toxicity, development, reproduction, mutagenicity, and carcinogenicity (Norris et al., 1973, 1974, 1975; Kociba
et al., 1975; National Toxicology Program, 1986; el Dareer et al.,
1987; Hardy et al., 2002, 2009). The European Union (EU) independently reviewed these same studies and concluded that the
manufacture and use of DecaBDE did not present a risk to human
health (European Commission, 2002). However, the EU did re-

Decabromodiphenyl ether (DecaBDE; CASRN 1163-19-5) has
been used as a flame retardant for approximately three decades.
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1
Reference dose: “An estimate (with uncertainty spanning perhaps an order of
magnitude) of a daily oral exposure to the human population (including sensitive
subgroups) that is likely to be without an appreciable risk of deleterious effects during
a lifetime. It can be derived from a no-observed-adverse-effect, lowest-observedadverse-effect, or benchmark dose, with uncertainty factors generally applied to
reflect limitations of the data used.” Source: http://www.epa.gov/IRIS/
help_gloss.htm#r.

ABBREVIATIONS: DecaBDE, decabromodiphenyl ether; BDE-209, 2,2⬘,3,3⬘,4,4⬘,5,5⬘,6,6⬘-decabromodiphenyl ether congener; EU, European
Union; DNT, developmental neurotoxicity; SPL, soyaphospholipon/Lutrol F 127-water; GD, gestation day; LD, lactation day; CO, corn oil; PND,
postnatal day; LOQ, limit of quantitation; BDE-28, 2,3,5-tribromodiphenyl ether; BDE-33, 2,3⬘,4⬘-tribromodiphenyl ether; BDE-47, 2,2⬘,4,4⬘tetrabromodiphenyl ether; BDE-99, 2,2⬘,4,4⬘,5-pentabromodiphenyl ether; BDE-100, 2,2⬘4,4⬘,6-pentabromodiphenyl ether; BDE-138,
2,2⬘,3,4,4⬘,5-hexabromodiphenyl ether; BDE-153, 2,2⬘,4,4⬘,5,5⬘-hexabromodiphenyl ether; BDE-154, 2,2⬘,4,4⬘,5,6⬘-hexabromodiphenyl ether;
DE-183, 2,2⬘,3⬘,4,4⬘,5⬘,6-heptabromodiphenyl ether; BDE-197, 2,2⬘,3,3⬘,4,4⬘6,6⬘-octabromodiphenyl ether.
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ABSTRACT:

EXPOSURE EVALUATION STUDY OF DecaBDE IN RATS
quire manufacturers to conduct a guideline-compliant developmental neurotoxicity (DNT) study under Good Laboratory Practice
standards (Organisation for Economic Co-operation and Development, 1997; European Commission, 2006). In addition, the EU
required evaluation of direct gavage administration to the pup and
use of an atypical vehicle, soyaphospholipon/Lutrol F 127-water
(SPL). These requests were based on reports of preliminary developmental neurotoxicity findings in neonatal mouse pups directly
administered BDE-209 (Viberg et al., 2001) and of BDE-209
absorption being enhanced when SPL was the vehicle (Mörck and
Klasson-Wehler, 2001).2
Until the report by Viberg et al. (2001), DecaBDE’s mammalian
toxicology database supported its safe use as a flame retardant, as
evidenced by no-observed-effect levels and no-observed-adverseeffect levels of ⱖ1000 mg/(kg 䡠 day) in repeated-dose studies (Hardy
et al., 2009). DecaBDE’s limited bioavailability3 was considered a
factor in its general lack of mammalian toxicity (National Toxicology
Program, 1986; el Dareer et al., 1987; Zhou et al., 2001). DecaBDE’s
low toxicity, marginal uptake, and low volume of distribution suggested that direct dosing of pups might be necessary to ensure adequate exposure.
The Organisation for Economic Co-operation and Development’s
guideline for developmental neurotoxicity testing requires maternal
administration of the test substance from gestation day (GD) 6
through lactation day (LD) 21 (Organisation for Economic Co-operation and Development, 2007). Adverse treatment-related pre- or
postnatal outcomes are considered evidence of adequate exposure to
the offspring, even when data on the dose received by the offspring
are not available. Direct dosing of preweaning animals is sometimes
used to resolve issues of the dose delivered to the offspring but may
complicate interpretation of results from a larger study (Zoetis and
Walls, 2003).
A two-phase study was performed to characterize the most appropriate route (i.e., direct or indirect administration to pups) and vehicle
[i.e., corn oil (CO) or SPL] for maximum delivery of DecaBDE to
offspring. In phase 1, plasma and/or milk concentrations were determined in the dams, fetuses, and/or nursing pups after repeated DecaBDE administration throughout gestation or during gestation and
lactation using CO or SPL as the vehicle. Dose levels of 100, 300, and
1000 mg/(kg 䡠 day) in CO were used for this phase of the study based
on the data generated from a previous prenatal developmental toxicity
study in rats using similar doses (Hardy et al., 2002). In addition, a
dose level of 1000 mg/(kg 䡠 day) in SPL served to provide comparative exposure data of DecaBDE when administered in CO versus
SPL. In phase 2, the impact of vehicle on plasma levels in pups
derived from naive dams was investigated after a single oral (gavage)
dose of DecaBDE in CO or SPL on postnatal day (PND) 4. The
objective of this work was to assist in the design and performance of
a DecaBDE DNT study in the rat by comparing the effects of time,
dose, and vehicle on plasma and milk levels and to provide information on DecaBDE fetal and neonatal plasma levels concurrent with
those in maternal plasma and milk for risk assessment use. In the
process, a method for the analysis of microliter samples of plasma and
milk was developed, and new insights into DecaBDE’s potential for
toxicity were generated.
2

Published as Viberg et al. (2003) and Mörck et al. (2003), respectively.
Throughout this report, the classic pharmacokinetic definitions for bioavailability and oral absorption will be used. Bioavailability is defined as the fraction
and rate of the administered dose reaching the systemic circulation as the parent
molecule. Oral absorption is defined as that fraction of the dose reaching the
portal vein as the parent molecule.
3
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Materials and Methods
Chemicals. The test substance was a composite that contained equal proportions of the three commercial DecaBDE products (CASRN 1163-19-5)
(Supplemental Fig. S1) of Albemarle Corporation (Baton Rouge, LA), Chemtura Corporation (Middlebury, CT), and ICL-IP America, Inc. (St. Louis, MO).
The composite was used to replicate previous studies (Hardy et al., 2002) and
provide a test substance representative of the three commercially available
DecaBDE materials. The composite was determined to be 97.51% BDE-209
with three impurities (i.e., nonabromodiphenyl ethers) at approximately 2.5%.
Before use, the composite was characterized for identity by Fourier transform
infrared spectroscopy, and its purity and homogeneity were determined by gas
chromatography. [13C12]DecaBDE (⬎98% BDE 209) was supplied by Cambridge Isotope Laboratories, Inc. (Andover, MA). Corn oil was obtained from
ACH Food Corporation (Memphis, TN). Phospholipon 90 NG and Lutrol F
127 NF Prill were obtained from American Lecithin Company (Oxford, CN)
and Mutchler, Inc. (Harrington Park, NJ), respectively. Deionized water was
prepared on site. Blank rat plasma and milk were acquired from Bioreclamation (East Meadow, NY).
Animals. A total of 245 sexually mature, virgin female Crl:CD(SD) rats,
approximately 70 days old at receipt, were obtained from Charles River
Laboratories, Inc. (Raleigh, NC). Females, approximately 11 weeks of age,
judged to be in good health and at a minimum of 220 g, were cohabitated (1:1)
with in-house males. Resident males were untreated, sexually mature rats used
exclusively for mating. The presence of a vaginal copulatory plug or sperm in
a vaginal lavage was considered positive evidence of mating. GD 0 was
defined as the day on which evidence of mating was observed. After mating,
females were randomly assigned to treatment groups based on stratification of
the GD 0 body weights using a block design. Animals were housed in
accordance with the Guide for the Care and Use of Laboratory Animals in
animal facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (National Research Council,
1996). Animals had ad libitum access to Certified Rodent LabDiet 5002 (PMI
Nutrition International, LLC, Parkway Mulberry, FL) and reverse osmosispurified drinking water. Animal room conditions were 71 ⫾ 5°F and 50 ⫾ 20%
relative humidity, 12-h light/dark photoperiod, and, at a minimum, 10 fresh air
changes per h.
Experimental Design. Plasma concentrations after oral (gavage) administration to Sprague-Dawley Crl:CD(SD) dams or pups using one of two vehicles, CO or SPL, and single or multiple doses were investigated from 0 to 24 h
after dosing. The doses administered to dams over GD 6 through LD 4, e.g.,
0, 100, 300, or 1000 mg/(kg 䡠 day) in CO were based on those of a prenatal
developmental study with DecaBDE (Hardy et al., 2002).
The study consisted of eight groups of rats (Table 1). Four groups of bred
female rats (n ⫽ 14 in the control group and 48 in the DecaBDE groups) were
administered the test article in CO by oral gavage at dose levels of 0, 100, 300,
or 1000 mg/(kg 䡠 day). Half of the animals in each dose group were treated
from GDs 6 through 20, whereas the remaining animals continued on treatment
through LD 4. On GD 20, half of the animals in each dose group were
euthanized, and blood was collected from dams and fetal litters. The remaining
animals were allowed to deliver, and dams and neonatal pups were euthanized
on LD 4. Blood was collected from dams and pups on LD/PND 4, and milk on
PND 4 was also collected from dams. Two to three rats were sampled at each
time point. Blood collection occurred immediately after dosing (0 h), and 0.5,
1, 2, 4, or 8 h after dosing. Milk collection occurred at 0.5, 1, 2, 4, 8, and 24 h
after dosing. Two groups of bred female rats were administered the SPL
vehicle with (n ⫽ 24) or without (n ⫽ 10) the test article at a dose of 1000
mg/(kg 䡠 day) over GD 6 through LD 4. Blood and milk collections were as
described above for animals administered the test article in CO.
Two groups of 18 naive bred females were allowed to deliver, and their
litters were randomly culled to 8 pups (4 males and 4 females, when possible)/
litter on PND 4. On PND 4, pups were administered a single 20 mg/kg dose of
the test article by gavage in either CO or SPL. The 20 mg/kg dose was selected
based on Viberg et al. (2003). Blood was collected at sacrifice on PND 4 at 0.5,
1, 2, 4, 8, or 24 h after dosing. Samples were analyzed for test article content,
based on quantitation of BDE-209. As an adjunct to the subsequent DNT
study, plasma and/or milk concentrations at two additional doses, 1 and 10
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TABLE 1
Description of the DecaBDE dosage regimens, sample types collected, and sampling intervals in F0 females, fetuses, and/or neonates
Naive Littersa (8 Pups/Litter);
Single Direct Dose to Pups on
PND 4

F0 Females; Multiple Doses
Group

Dosage Level

GDs 6 through 20

Vehicle

b

GD 6 through LD 4

No. Females

GD 20 Samplesd

No. Females

4f
24
24
24
—
—
—
—
—
—

Blood
Blood
Blood
Blood
—
—
—
—
—
—

10f
24
24
24
—
—
10d
24
3–4
3–4

c

LD 4, PND 4 Samplese

No. Pups

PND 4 Sample

—g
—
—
—
18
18
—
—
—
—

—
—
—
—
Blood
Blood
—
—
—
—

mg/(kg 䡠 day)

1
2
3
4
5
6
7
8
A1h
A2h

0
100
300
1000
20
20
0
1000
1
10

CO
CO
CO
CO
CO
SPL
SPL
SPL
CO
CO

Milk
Milk
Milk
Milk

and
and
and
and

Milk
Milk
Milk
Milk

and
and
and
and

blood;
blood;
blood;
blood;
—
—
blood;
blood;
blood;
blood;

blood
blood
blood
blood
blood
blood
blood
blood

a

Not previously exposed to DecaBDE.
Samples were collected at 0 (predose) and at 0.5, 1, 2, 4, and 8 h after dosing on each day of sampling, except as indicated for controls.
Samples were collected at 0.5, 1, 2, 4, 8, and 24 h after dosing on each day of sampling, except as indicated for controls.
d
F0 females and fetuses (GD 20).
e
F0 females (LD 4) and pups (PND 4).
f
Blood collected only at 1 h.
g
—, not performed.
h
A, adjunct; samples collected at 8 h after dosing only on LD 4/PND 4.
b
c

mg/(kg 䡠 day), administered on GD 6 to LD 4, were determined in three or four
F0 females per group and their litters 8 h after dosing on LD 4.
Body weights and food consumption of the dams were measured on GDs 0,
6, 9, 12, 15, 18, and 20 and on LDs 1, 4, 7, 11, 14, 17, 21, and 22. Pups were
individually weighed on PNDs 1, 4, 7, 11, 14, and 21.
Blood and Milk Collection. Maternal (lateral tail vein or vena cava) and
fetal (umbilical vessels) blood samples were collected into chilled tubes
containing lithium heparin. Pups were euthanized by decapitation, and trunk
blood was collected. Fetal and pup blood samples were pooled by litter. Plasma
was isolated from whole blood in a refrigerated centrifuge. Females were
separated from their litters 5.5 h before milk collection, and oxytocin, 1 IU
(0.05 ml) subcutaneously, was administered to stimulate milk letdown. Milk
was collected from the same dams as used for blood collection (four dams per
group per time point; vehicle control rats were sampled at 4 h after dosing
only). The mammary glands were cleaned, and milk was collected using gentle
massage over the glands until sufficient sample size was achieved. Plasma and
milk samples were stored frozen (⫺20°C) until analyzed.
Analysis of Test Article Formulations, Plasma, and Milk. Test articlevehicle formulations were prepared weekly or as needed, divided into
aliquots for daily use, and stored refrigerated and protected from light.
Analyses were performed using gas chromatography with electron capture
detection. The method was validated over the range of DecaBDE concentrations administered (Coffee, 2008). Rat plasma and milk samples were
analyzed by gas chromatography (6890N; Agilent Technologies, Santa
Clara, CA)-mass spectrometry (5975C; Agilent) with use of an electron
ionization source. The method was validated for 100-l sample volumes
before use over the concentration ranges of 1000 through 6000 and 250
through 6000 ng of DecaBDE/ml in rat plasma and milk, respectively
(O’Lear, 2009). The method used liquid-liquid extraction of DecaBDE and
[13C12]DecaBDE as the internal standard. Valid analytical runs were required to have at least two thirds of the quality control samples and at least
one third at each level to be within 85 to 115% of the target quality control
concentration. Pharmacokinetic parameters were analyzed using WinNonlin
5.2 Professional (Pharsight Corp., Mountain View, CA). Details on the materials and methods, statistics, and additional endpoints evaluated in the study are
available in the supplemental data.

Results
Mortality, Morbidity, Body Weights, Food Consumption, and
Gestational and Litter Data. No test substance-related deaths or
clinical signs of toxicity occurred in the F0 females, when CO was the
vehicle used to deliver the test substance. In addition, no test sub-

stance-related differences in mean body weight, body weight gain, or
food consumption were detected during gestation or lactation (Supplemental Tables S1–S3). When SPL was the vehicle, mean food
consumption by maternal animals was increased in the 1000-mg/(kg 䡠
day) group compared with the SPL control group on LDs 11 through
24, 14 through 17, 17 through 21, 21 through 22, and 1 through 22
( p ⬍ 0.05 or 0.01) (Supplemental Table S3). Food consumption for
the SPL 1000-mg/(kg 䡠 day) group was similar to that of the CO
control over these intervals (Supplemental Table S3), as was body
weight gain (Supplemental Tables S1 and S2).
DecaBDE administration in CO or SPL did not affect gestation or
litter parameters (Supplemental Table S4). Mean gestational length in
treated animals was comparable with that of their respective vehicle
controls and similar to the laboratory’s historical control database
(mean 21.9 days). The mean number of pups born, percentage of
males at birth, mean live litter size, and postnatal survival were similar
between control groups and their respective treatment groups.
Mean offspring body weights and weight gains through PND 21 in
the CO-treated groups were similar to CO control and/or laboratory
historical control means (Table 2; Supplemental Table S5). Body
weights of male and female pups in the SPL 1000-mg/(kg 䡠 day) group
were higher than those in their respective SPL control group on PNDs
7, 11 (females only), 14, and 21 ( p ⬍ 0.05 or 0.01). Body weight
gains were also increased in the SPL 1000-mg/(kg 䡠 day) male and
female pups on PNDs 4 through 7 and 17 through 21. In contrast,
mean body weights in the SPL control group were consistently lower
than those of litters derived from CO control dams. Furthermore, body
weight gains by SPL control pups of both sexes were found to be
approximately 66 to 88% of the CO control pups’ gains.
Plasma Concentrations in Dams and Fetal Litters on GD 20.
DecaBDE plasma concentrations in dams and their litters just before
and up to 8 h after dosing on GD 20 with CO as the vehicle are shown
in Fig. 1 (Supplemental Table S6). The dams’ mean plasma concentrations were similar at each time point regardless of dose [100, 300,
or 1000 mg/(kg 䡠 day)]. Furthermore, DecaBDE concentrations were
relatively constant, regardless of dose, over the entire sampling interval. A similar lack of dose and time response was seen in fetal plasma,
but levels were typically 2.5- to 5-fold lower than those of the dams
(Table 3).
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TABLE 2
F1 pup body weights on PNDs 1 through 21

F1 pups derived from females administered DecaBDE at doses of 100 to 1000 mg/(kg 䡠 day) in CO or 1000 mg/(kg 䡠 day) in SPL from GD 6 through LD 22. Data are means ⫾ S.E.M.
Body Weight with Maternal Dose (GD 6 through LD 21) and Vehicle
PND

CO (n ⫽ 9)

a

CO 100 (n ⫽ 22)

CO 300 (n ⫽ 24)

CO 1000 (n ⫽ 22)

SPL (n ⫽ 10)

SPL 1000 (n ⫽ 22)

g

F1 males
1
4
7
11
14
17
21
F1 females
1
4
7
11
14
17
21

7.6 ⫾ 0.27
10.3 ⫾ 0.48
16.9 ⫾ 0.90
26.6 ⫾ 1.27
33.6 ⫾ 1.51
41.1 ⫾ 1.79
51.6 ⫾ 2.25

7.5 ⫾ 0.14
10.4 ⫾ 0.23
16.9 ⫾ 0.34
26.6 ⫾ 0.61
33.4 ⫾ 0.79
39.4 ⫾ 0.93
50.7 ⫾ 1.19

7.3 ⫾ 0.10
9.9 ⫾ 0.19
16.2 ⫾ 0.32
25.7 ⫾ 0.45
31.9 ⫾ 0.54
38.1 ⫾ 0.66
48.8 ⫾ 0.74

7.3 ⫾ 0.14 (n ⫽ 23)
9.8 ⫾ 0.27 (n ⫽ 23)
15.9 ⫾ 0.48
25.5 ⫾ 0.61
31.4 ⫾ 0.68
38.8 ⫾ 0.73
48.1 ⫾ 1.15

6.7 ⫾ 0.15
8.0 ⫾ 0.27
11.5 ⫾ 0.73
19.2 ⫾ 1.45
25.8 ⫾ 1.66
32.9 ⫾ 1.86
41.9 ⫾ 2.53

6.8 ⫾ 0.13 (n ⫽ 23)
8.6 ⫾ 0.20 (n ⫽ 23)
13.5 ⫾ 0.42*
21.9 ⫾ 0.65
29.2 ⫾ 0.74*
36.0 ⫾ 0.90
47.6 ⫾ 0.84*

7.1 ⫾ 0.27
9.6 ⫾ 0.54
16.0 ⫾ 0.86
25.6 ⫾ 1.39
32.1 ⫾ 1.87
39.0 ⫾ 1.99
49.2 ⫾ 2.51

7.1 ⫾ 0.12
9.6 ⫾ 0.23
15.8 ⫾ 0.27
25.1 ⫾ 0.56
32.2 ⫾ 0.67
38.3 ⫾ 0.79
49.2 ⫾ 1.03

6.9 ⫾ 0.10
9.4 ⫾ 0.16
15.3 ⫾ 0.32
24.4 ⫾ 0.53
30.3 ⫾ 0.61
36.4 ⫾ 0.75
46.6 ⫾ 0.95

7.0 ⫾ 0.15 (n ⫽ 23)
9.3 ⫾ 0.25 (n ⫽ 23)
15.2 ⫾ 0.42
24.7 ⫾ 0.48
30.9 ⫾ 0.58
37.6 ⫾ 0.66
47.2 ⫾ 0.94

6.2 ⫾ 0.09
7.5 ⫾ 0.24
10.5 ⫾ 0.59
17.7 ⫾ 1.16
24.2 ⫾ 1.43
31.5 ⫾ 1.74
39.5 ⫾ 2.08

6.4 ⫾ 0.12
8.0 ⫾ 0.18
12.3 ⫾ 0.35*
20.3 ⫾ 0.58*
27.4 ⫾ 0.76*
34.1 ⫾ 0.84
44.4 ⫾ 0.98*

a
Number of litters.
* Significantly different from SPL control ( p ⬍ 0.05).

Plasma and Milk Concentrations in Dams on LD 4. Plasma
concentrations in dams at 0.5 to 24 h after dosing on LD 4 after
administration in CO over GD 6 through LD 4 are shown in Fig. 2
(Supplemental Tables S7 and S8). The plasma concentration patterns of
the dams administered the test article in CO were similar to those on GD
20. LD 4 plasma concentrations at each time point were similar at 100,
300, and 1000 mg/(kg 䡠 day). The AUClast for the CO test substance
groups were similar on LD 4 across a 10-fold dose range. In contrast,
exposure to DecaBDE for dams administered 1000 mg/(kg 䡠 day) over
GD 6 through LD 4 in SPL was 4- to 5-fold lower than that in CO
(Fig. 3; Table 3).
Mean milk concentrations at doses of 100 to 1000 mg/(kg 䡠 day) in
CO were relatively stable between 0.5 and 8 h after dosing, and were
similar irrespective of dose (Fig. 4; Table 3). Milk concentrations
were generally lower than plasma concentrations. In contrast, milk
concentrations in females administered DecaBDE in SPL at 1000
mg/(kg 䡠 day) over GD 6 through LD 4 were below the limit of
quantitation (LOQ) in 71% of the samples (Supplemental Table S8).
Where detected, the levels were 45 to 60% of those in the CO 1000
mg/(kg 䡠 day) group.
LD 4 blood and milk were collected at 8 h after dosing in the DNT
study from dams administered DecaBDE in CO at 1 or 10 mg/(kg 䡠
day) from GD 6 through LD 4 (Supplemental Tables S7 and S8). The
mean plasma (1700 ⫾ 540 ng/ml) and milk (1250 ⫾ 195 ng/ml)
concentrations in the CO 10 mg/(kg 䡠 day) group were similar to those

FIG. 1. DecaBDE plasma concentrations (nanograms per milliliter) on GD 20 in F0
dams (D) and fetuses (F) after administration of DecaBDE in CO at 100, 300, and
1000 mg/(kg 䡠 day) to F0 dams from GDs 6 through 20. Mean ⫾ S.D.

in the CO 100 to 1000 mg/(kg 䡠 day) groups. The mean plasma (510 ⫾
89 ng/ml) and milk (⬍LOQ; 509 ng/ml) concentrations at 1 mg/(kg 䡠
day) were lower.
Plasma Concentrations in Corresponding PND 4 Pups. The
PND 4 mean plasma concentrations in the CO 100 to 1000 mg/(kg 䡠
day) groups were similar over dose groups and time, suggesting a
lack of dose response and consistency among exposures across the
dose range (Fig. 2; Table 3; Supplemental Table S7). Pup plasma
concentrations and AUClast were roughly 2-fold higher than those
in dams’ plasma (Table 3). Like the CO 1000 mg/(kg 䡠 day) group,
the mean PND 4 plasma concentrations in nursing pups from the
SPL 1000 mg/(kg 䡠 day) group were roughly stable over time and
higher than the dams’ plasma concentrations (Fig. 3). However, the
PND 4 pups mean plasma concentrations in the SPL 1000 mg/(kg 䡠
day) group were clearly (approximately 3-fold) lower than those in
the CO 1000 mg/(kg 䡠 day) group (Supplemental Table S7).
PND 4 plasma samples were collected from pups at 8 h after dosing
of the maternal females with CO at doses of 1 or 10 mg/(kg 䡠 day) in
the DNT study (Supplemental Table S7). Like the dams’ LD 4 plasma
and milk, the pup mean plasma concentration (2140 ⫾ 257 ng/ml) in
the CO 10 mg/(kg 䡠 day) group was similar to those of the CO 100 and
1000 mg/(kg 䡠 day) groups, whereas that in the 1 mg/(kg 䡠 day) group
(929 ⫾ 124 ng/ml) was approximately 2.5-fold lower (Supplemental
Table S7).
Plasma Concentrations in Pups on PND 4 after a Single Dose.
Plasma concentrations after a single 20 mg/kg dose in CO to pups
on PND 4 increased with time after dosing from ⬍LOQ to 1845 ⫾
323 ng/ml at 0.5 and 24 h after dosing, respectively (Supplemental
Table S9). The peak level was within the range of PND 4 pups
derived from dams administered the test substance in CO from GD
6 through LD 4. Plasma concentrations on PND 4 ranged from
⬍LOQ to 293 ⫾ 29 ng/ml after a single 20 mg/kg dose in SPL
and were clearly lower than those achieved with CO. Both the
AUC0 – 8 h and the AUC0 –24 h were lower in directly dosed pups,
compared with pups receiving DecaBDE indirectly via the dams
(Table 3). Additional details on these results, including tabulated
values for figures and data not shown, are provided in the supplemental data.
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AUClast, the area under the plasma compound concentration vs. time curve from nominal time 0 to the last time point with quantifiable plasma compound concentration (Tlast). Calculated by linear trapezoidal summation using the equation AUClast ⫽ 兺
(0.5 ⫻ (y1 ⫹ y2) ⫻ ⌬t), where y1 and y2 are successive plasma compound concentrations and ⌬t is the sampling interval, in hours, between y1 and y2; Cavg, the average concentration in plasma at steady state. Cavg ⫽ AUC/. AUC ⫽ the area under the
plasma compound concentration vs. time curve from nominal time 0 to  ( ⫽ dosing interval); Cmax, Cmin, the observed maximum (minimum) concentration in plasma determined directly from the data; fluctuation %, percent fluctuation from the average
concentration in plasma at steady state. Fluctuation % ⫽ 100* (Cmax ⫺ Cmin)/Cavg; dose norm AUClast, Cavg, AUC0 – 8 hr, Cmax, dose normalized; AUClast, Cavg, AUC0 – 8 hr,Cmax divided by the daily dose in mg/(kg 䡠 day).
—, not calculated.

AUClast (h 䡠 ng/ml)
Cavg (ng/ml)
Cmax (ng/ml)
Cmin (ng/ml)
Fluctuation (%)
Dose norm AUClast
Dose norm
Cavg
AUC0–8 h (h 䡠 ng/ml)
AUC0–24 h (h 䡠 ng/ml)
Dose norm AUC0–8 h
Dose norm Cmax

Parameter (units)

TABLE 3

Summary of toxicokinetic parameters of DecaBDE for plasma and milk from dams on GD 20 or LD 4 and plasma from pups on GD 20 or PND 4
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FIG. 2. DecaBDE plasma concentrations (nanograms per milliliter) on LD 4 in F0
dams (D) and pups (P) after administration of DecaBDE in CO at 100, 300, and
1000 mg/(kg 䡠 day) to F0 dams from GD 6 through LD 4. Mean ⫾ S.D.

FIG. 3. Comparison of DecaBDE plasma concentrations in dams (D) and pups (P)
on LD 4/PND 4 after administration of DecaBDE in CO or SPL at 1000 mg/(kg 䡠
day) to F0 dams over GD 6 through LD 4. Mean ⫾ S.D.

FIG. 4. Comparison of DecaBDE plasma and milk concentrations (nanograms per
milliliter) on LD 4 of F0 dams after administration in CO at 100, 300, and 1000
mg/(kg 䡠 day) or SPL at 1000 mg/(kg 䡠 day) over GD 6 through LD 4. Mean ⫾ S.D.

Discussion

Several studies have reported limited absorption of DecaBDE after
oral administration (National Toxicology Program, 1986; el Dareer et
al., 1987; Huwe et al., 2008). For example, the U.S. National Toxicology Program reported dietary absorption of approximately 0.33%
of the dose by rats. However, 10% absorption from a single gavage
dose, when SPL was used as the delivery vehicle, was reported in rats
based on levels detected in bile (Mörck et al., 2003). SPL was chosen
in that study after higher solubility of DecaBDE in SPL, compared
with two other vehicles, was demonstrated. The 10% value was
subsequently interpreted as representing systemic absorption (i.e.,
bioavailability) without taking into account the negligible blood levels
reported by Mörck et al. (2003) and others. Also not taken into
consideration was the likelihood of extensive first-pass elimination, as
suggested by the concentrations in bile versus blood. However, based
on these data, the European Union was interested in use of SPL as the
vehicle in a guideline-compliant DNT study to assure maximum
exposure to pups.
The present study was conducted to determine the most appropriate
vehicle (CO or SPL) and method of administration (maternal or pup)

EXPOSURE EVALUATION STUDY OF DecaBDE IN RATS
for the DNT study by investigating blood plasma and/or milk levels in
the dam and/or pups. Information on gestational and lactational parameters as a function of dose and vehicle was also obtained. These
data demonstrated that administration of DecaBDE in CO at doses of
100, 300, and 1000 mg/(kg 䡠 day) from GDs 6 through 20 or GD 6
through LD 4 did not adversely affect the maternal animals or their
litters. The absence of maternal or fetal toxicity was consistent with
the results of an earlier prenatal developmental study in which doses
up to 1000 mg/(kg 䡠 day) were administered from GDs 0 through 20
(Hardy et al., 2002).
Although not compared statistically, visual inspection of the data
showed that mean body weights in lactating SPL control dams were
typically lower than those in CO administered dams. Food consumption in the SPL control dams was also lower than CO control or CO
1000 mg/(kg 䡠 day) dams, whereas food consumption in the SPL 1000
mg/(kg 䡠 day) dams approached that of the dams treated with a test
substance using CO. Furthermore, mean body weights of pups derived
from dams administered repeated doses of the SPL vehicle were lower
than those of pups derived from the CO test substance-treated dams
over PNDs 7 through 21. This reduction in body weight was not
observed in pups derived from dams administered DecaBDE in the
CO vehicle.
The SPL-induced reduction in pup body weight precluded its use in the
DNT study, and on this basis alone CO appeared to be a more suitable
vehicle. However, SPL also negatively affected plasma and milk concentrations in the dams and/or pups. DecaBDE plasma concentrations in
LD 4 dams and PND 4 pups were lower when animals were administered
1000 mg/(kg 䡠 day) over GD 6 through LD 4 using SPL as the vehicle
instead of CO. DecaBDE concentrations in milk were also lower than
those achieved with CO, when administered to dams in SPL over GD 6
through LD 4. Likewise, DecaBDE plasma concentrations were lower in
naive pups administered a single direct dose on PND 4, when SPL was
the vehicle instead of CO. These plasma concentrations were also substantially lower than those of pups derived from dams administered
DecaBDE in CO at 1000 mg/(kg 䡠 day) from GD 6 through LD 4. Thus,
contrary to the expected increase in bioavailability, SPL produced lower
DecaBDE concentrations, often below detection, in maternal and neonatal plasma and/or milk than equivalent doses administered in CO.
With CO as the vehicle, DecaBDE plasma concentrations in dams
and fetal litters appeared to be at steady-state levels when first
sampled on GD 20; plasma concentrations were similar at the first
(immediately before dosing) and last (8 h) collection times after 15
consecutive doses. Steady-state was also apparent in dam and neonatal
pup plasma concentrations measured on LD 4 after dosing from GD
6 to LD 4. Steady-state was likely reached within a few days of dose
initiation, but blood samples were first collected after 15 daily doses.
Attainment of steady-state levels during this time frame is consistent
with elimination of ⬎99% of a dietary dose within 72 h (National
Toxicology Program, 1986), as well as the 2008 report of Huwe et al.
noting that brominated congeners BDE-28/33, -47, -99, -100, -138,
-153, -154, -183, and -197 reached steady state in rat adipose tissue by
day 14 of treatment. Given that steady state is typically reached within
five to seven half-lives, the results of Huwe et al. (2008) further
suggest that adipose half-lives of 0.4 to 2.8 days are likely for these 10
lower brominated congeners. Although a component in the test mixture administered in the study of Huwe et al. (2008), BDE 209 was not
included in the estimate of time to steady state or adipose half-life
because it was not detected in adipose tissue. These half-lives represent a worst case, because adipose tissue is poorly perfused with
typically longer (re)distribution times than other tissues. When viewed
in total, our data along with other reports (Norris et al., 1973, 1974,
1975; el Dareer et al., 1987) demonstrate that DecaBDE and presumed
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lower brominated diphenyl ether congeners do not have half-lives
consistent with highly bioaccumulative substances and suggest that a
concern for unrealized adverse effects due to extremely long half-lives
is not relevant.
For the first time DecaBDE plasma concentrations were shown to
plateau at oral doses ⱖ10 mg/(kg 䡠 day). Plasma levels in rats were
generally indistinguishable over a dose range of 2 orders of magnitude, i.e., 10 to 1000 mg/(kg 䡠 day), in dams, fetal litters, and neonatal
pups. Fetal plasma and maternal milk concentrations were lower than
maternal plasma concentrations, whereas neonatal plasma concentrations were similar to or higher than maternal plasma concentrations.
The lack of dose response in maternal plasma concentrations may be
due to a combination of factors, including binding to fecal macromolecules, diffusion-limited uptake from the gut into the portal circulation, and efficient first-pass elimination in the bile, such that only a
small fraction of the dose is bioavailable.
DecaBDE is expected to bind to particulates, including those found
in fecal matter, and evidence for this is seen in studies reporting a
substantial fraction of the dose could not be extracted from the feces
(National Toxicology Program, 1986; el Dareer et al., 1987; Mörck et
al., 2003; Huwe and Smith, 2007; Huwe et al., 2008). However, the
binding properties of DecaBDE have led to different conclusions
regarding its fate in the body. For example, Huwe and Smith (2007)
reported nonextraction of BDE-209 from feces as evidence for metabolism; this conclusion was subsequently reinterpreted later as poor
recovery by the same authors (Huwe et al., 2008). Likewise, Mörck et
al. (2003) concluded that 65% of an oral dose of [14C]BDE-209 was
present in the gut as metabolites. These authors defined metabolites as
all 14C activity not extracted with the parent molecule, including that
engaged in nonspecific binding. However, other studies using 14Clabeled test articles have demonstrated that after oral administration,
DecaBDE is poorly metabolized and predominantly excreted in the
feces as parent molecule (National Toxicology Program, 1986; el
Dareer et al., 1987; Huwe et al., 2008; Riu et al., 2008).
Bioavailability after oral dosing is dependent on the rate and extent
of absorption and systemic clearance (van de Waterbeemd and Testa,
2009). Absorption is dependent on solubility, permeability, gut wall
metabolism, and cellular transporters. The rate of absorption from
the gut lumen can be limited by the dissolution rate. For poorly
soluble compounds such as DecaBDE, dissolution can be the
rate-limiting factor for absorption. Absorption is also dependent on
the permeability of the substance through the intestinal tract membrane. Molecular factors affecting permeability are solubility, flexibility, H bonding, molecular size/shape, and lipophilicity. DecaBDE’s molecular weight (959.2) probably imparts a negative
effect on its permeability, as does the molecule’s noncoplanar
spatial arrangement and limited solubility (water solubility ⬍0.1
g/l). These properties suggest DecaBDE’s oral absorption would
be slow and limited, as was found in the present study and
previously reported by others (National Toxicology Program,
1986). Furthermore, the present results suggest DecaBDE’s absorption may be governed by zero-order kinetics. That is, at doses
ⱖ10 mg/(kg 䡠 day), a constant amount of DecaBDE was absorbed
per unit time, whereas first-order kinetics (a constant fraction of
the administered dose) probably governed absorption at the dose of
1 mg/(kg 䡠 day). Figure 1 of Sandholm et al. (2003) suggests
first-order absorption kinetics at a dose of approximately 2 mg/kg
based on the similar terminal slopes of the oral and intravenous
concentration-time curves. If zero-order kinetics were operative at
this dose, different slopes would be expected. Therefore, the transition point between first- and zero-order absorption kinetics appears to occur between 1 (or possibly 2) and 10 mg/(kg 䡠 day).
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A similar lack of dose response in fetal plasma and maternal milk
suggests that maternal plasma concentrations dictate DecaBDE concentrations in these compartments. The generally lower concentrations detected in fetal plasma and milk also suggests that DecaBDE’s
distribution from the maternal circulation into these compartments is
limited. These results are consistent with those of Riu et al. (2008),
who reported 0.43% distribution of the dose to fetal litters. The higher
plasma concentrations of DecaBDE in neonates (nursing pups) compared with the plasma concentrations in dams suggests, as expected
because of immature hepatic excretory function, that these pups
eliminate DecaBDE more slowly than adult rats.
In conclusion, new information was generated on the relationships between maternal, fetal, and neonatal plasma and maternal
milk DecaBDE concentrations after repeated dosing in the rat. This
study suggests that DecaBDE steady-state plasma concentrations
in the rat are achieved within 14 daily doses and possibly sooner.
In addition, for the first time, maximal DecaBDE concentrations
were shown to occur in rat plasma and milk at oral doses as low as
10 mg/(kg 䡠 day). Increasing the oral dose to 1000 mg/(kg 䡠 day) did
not result in a corresponding increase in plasma or milk DecaBDE
concentrations.
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